Table 1.
Characteristics (mean ± SD) at baseline for LYM-X-SORB™ (LXS) and Placebo groups, and for male and female participants.
| All n=63 |
LXS n=27 |
Placebo n=36 |
Male n=36 |
Female n=27 |
|
|---|---|---|---|---|---|
| Sex, % males | 57 | 61 | 52 | 100 | 0 |
| Age, y | 10.6 ±2.9 | 11.0±2.8 | 10.2 ±2.9 | 11.0 ± 2.5 | 10.1 ±3.2 |
| Pubertal Tanner stage, % | |||||
| 1 | 47 | 42 | 50 | 46 | 48 |
| 2 | 29 | 31 | 28 | 31 | 26 |
| 3 | 13 | 15 | 11 | 14 | 11 |
| 4 | 10 | 12 | 8 | 6 | 15 |
| 5 | 2 | 0 | 3 | 3 | 0 |
| Genotype, ΔF508/508, % | 57 | 56 | 58 | 58 | 56 |
| HAZ | −0.5 ±0.9 | −0.2 ±0.9 | −0.7 ±0.9 | −0.4 ±0.7 | −0.6 ± 1.1 |
| WAZ | −0.4 ±0.7 | −0.5 ±0.6 | −0.3 ± 0.7 | −0.4 ±0.7 | −0.5 ±0.7 |
| BMIZ | −0.2 ±0.7 | −0.5 ±0.6 | 0.1 ±0.7*** | −0.2 ±0.6 | −0.2 ±0.8 |
| Body Composition | |||||
| FFM, kg | 26.3 ± 9.4 | 26.8 ±8.1 | 26.0 ±10.4 | 28.5 ±9.8 | 23.5 ±8.2* |
| FM, kg | 7.1 ±2.6 | 7.3 ±2.8 | 6.9 ±2.5 | 6.6 ±2.6 | 7.7 ±2.5 |
| Fat, % | 21.6 ±5.7 | 21.5 ± 5.1 | 21.7±6.2 | 18.9± 5.0 | 25.1 ±4.6*** |
| UAMAZ | −0.6 ±0.8 | −0.8 ±0.8 | −0.4 ±0.8 | −0.6 ±0.9 | −0.5 ±0.7 |
| UAFAZ | −0.3 ±0.8 | −0.4 ±0.8 | −0.2 ±0.9 | −0.3 ±0.7 | −0.3 ± 1.0 |
| FEV1, % pred | 96 ±22 | 92 ±21 | 100 ± 22 | 92 ±28 | 88 ±27 |
| REE, kcal/d | 1300 ±256 | 1314 ±222 | 1290 ± 282 | 1385 ±264 | 1187± 198** |
| REE% | 108.5 ±8.3 | 108.8 ±8.6 | 108.3 ±8.1 | 109.0 ±8.4 | 107.9 ±8.2 |
*
Differences significant at p<0.05;
**
p<0.01;
***
p<0.001.
BMIZ - Body mass index-Z-score; FFM - Fat free mass (kg); FM - Fat mass (kg); HAZ - Height-Z-score; REE - Resting energy expenditure; UAFAZ - Upper arm fat area Z-score; UAMAZ - Upper arm muscle area Z-score; WAZ - Weight-Z-score